Janux Therapeutics (JANX) Cash from Operations (2020 - 2025)
Historic Cash from Operations for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to -$12.9 million.
- Janux Therapeutics' Cash from Operations fell 47624.38% to -$12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$70.4 million, marking a year-over-year decrease of 9037.04%. This contributed to the annual value of -$43.8 million for FY2024, which is 1336.83% up from last year.
- Janux Therapeutics' Cash from Operations amounted to -$12.9 million in Q3 2025, which was down 47624.38% from -$23.8 million recorded in Q2 2025.
- In the past 5 years, Janux Therapeutics' Cash from Operations registered a high of $5.6 million during Q1 2021, and its lowest value of -$23.8 million during Q2 2025.
- In the last 5 years, Janux Therapeutics' Cash from Operations had a median value of -$11.7 million in 2023 and averaged -$10.9 million.
- Its Cash from Operations has fluctuated over the past 5 years, first plummeted by 54340.09% in 2021, then skyrocketed by 8094.63% in 2024.
- Janux Therapeutics' Cash from Operations (Quarter) stood at -$10.5 million in 2021, then fell by 13.66% to -$11.9 million in 2022, then grew by 16.89% to -$9.9 million in 2023, then plummeted by 68.92% to -$16.7 million in 2024, then increased by 23.13% to -$12.9 million in 2025.
- Its last three reported values are -$12.9 million in Q3 2025, -$23.8 million for Q2 2025, and -$17.0 million during Q1 2025.